Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- Advisory bodies and committees (219)
- Scheduling (national classification system) (59)
- Therapeutic goods regulation (43)
- Regulatory compliance (27)
- In Vitro Diagnostic medical devices (IVDs) (26)
- Manufacturing (26)
- Prescription medicines (24)
- Advertising (22)
- Non-prescription medicines (20)
- Unique Device Identification (UDI) hub (20)
- Registered complementary medicines (17)
- Complementary medicines (16)
- COVID-19 vaccines (14)
- Over the counter (OTC) medicines (10)
- Safety (10)
- Australian Register of Therapeutic Goods (ARTG) (9)
- Clinical trials (9)
- Medical devices safety (9)
- Legislation (8)
- Medicine safety (8)
- Vaping hub (8)
- Medicinal cannabis hub (5)
- Listed medicines (3)
- Shortages (3)
- Advanced therapies (2)
- Breast implant hub (2)
- Compliance and enforcement hub (2)
- Pharmacovigilance (2)
- Alert/Advisory (1)
- Blood and blood components (1)
- Cosmetics (1)
- Import and export (1)
- Labelling and packaging (1)
- TGA conformity assessment certification (1)
Search
452 result(s) found, displaying 101 to 125
-
PresentationsPresented at the 2023 ARCS Annual Conference
-
PresentationsPresented at the 2023 ARCS Annual Conference
-
PresentationsPresented at the 2023 ARCS Annual Conference
-
PresentationsPresentations given by the TGA at the 2023 ARCS Annual Conference, 6-8 June 2023.
-
PresentationsPresented at the 2023 ARCS Annual Conference
-
-
-
Committee meetingsAdvisory Committee on Complementary Medicines (ACCM) meeting
-
Committee meetingsAdvisory Committee on Medical Devices (ACMD) meeting
-
-
-
WebinarsUDI Webinar 16 – Australian UDI update and guest speakers on the value of UDI for procurement and inventory management in hospitals.
-
Committee meetingsThe 3rd meeting of the Women's Health Product Working Group (WHPWG #3), March 2023
-
PresentationsThe TGA Good Manufacturing Practice Forum returned to Sydney on 21 March 2023.
-
PresentationsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be conditionally classified as Schedule 8 (controlled drug) in the Poisons Standard.
-
WebinarsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) when prescribed by a psychiatrist.
-
WebinarsIn this webinar we will provide an update on the Australian UDI implementation and discuss the challenges and benefits of having UDI in healthcare and the role of hospitals and other healthcare providers in relation to using UDI.
-
-
Committee meetingsAdvisory Committee on Medical Devices (ACMD) meeting
-
-
PresentationsThis webinar will explain labelling requirements for finished MCP in detail.
-
Committee meetingsThe 2nd meeting of the Women's Health Product Working Group (WHPWG #2), October 2022
-
-
PresentationsThis webinar will guide you through the process of charging for regulatory activities, the medicinal cannabis funding model and the fees and charges structure and amounts proposed to commence on 1 July 2023.
-
WebinarsThe final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.